INO — Inovio Pharmaceuticals, Inc.

Summary of Inovio's Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of December 31, 2025, Inovio reported $58.5 million in cash, down from $94.1 million a year prior.
• Operating Expenses: Decreased from $20.5 million in Q4 2024 to $17.5 million in Q4 2025. Full-year operating expenses dropped 23% from $112.6 million in 2024 to $86.9 million in 2025.
• Net Income/Loss: Reported a net income of $3.8 million for Q4 2025, primarily due to a $21.2 million noncash gain related to warrant liabilities. The full-year net loss was $84.9 million, or $1.81 per share.

2. Strategic Updates and Business Highlights

• BLA for INO-3107: The FDA accepted Inovio's Biologics License Application (BLA) for INO-3107 under the accelerated approval program, with a PDUFA date set for October 30, 2026. However, the FDA raised concerns regarding the adequacy of information for eligibility under this program.
• Cost Management: Inovio has taken measures to extend its cash runway into Q4 2026, including a 15% reduction in workforce and project rescoping.
• Partnerships: Announced a collaboration with Dana-Farber Cancer Institute and Akeso to evaluate INO-5412 in a Phase II trial for glioblastoma, leveraging their checkpoint inhibitor.

3. Forward Guidance and Outlook

• Cash Runway: The company estimates its cash runway will last into Q4 2026, with a projected operational net cash burn of approximately $22 million for Q1 2026.
• Regulatory Focus: The primary goal remains advancing INO-3107 towards FDA approval while continuing to develop other pipeline candidates, particularly in rare diseases.

4. Bad News, Challenges, or Points of Concern

• FDA Concerns: The FDA's preliminary conclusion regarding inadequate justification for accelerated approval eligibility poses a significant challenge. The company is awaiting a meeting date to discuss this further.
• Cash Burn: The operational net cash burn is expected to be higher in Q1, raising concerns about financial sustainability without additional capital raising.
• Competitive Landscape: The market for RRP treatments is competitive, particularly with existing therapies like PAPZIMEOS, which could impact market acceptance of INO-3107.

5. Notable Q&A Insights

• FDA Discussions: In response to questions about the upcoming FDA meeting, Inovio clarified that no new clinical data would be submitted but emphasized the importance of their assessment aid submitted in February.
• Launch Preparations: The company is well-prepared for a potential launch of INO-3107, having engaged in extensive market research and selected commercial partners.
• Pipeline Development: Inovio indicated that if INO-3107 is approved, they would consider advancing other candidates like 3112, depending on available resources.

This summary encapsulates the key points from Inovio's Q4 2025 earnings call, highlighting both the progress made and the challenges faced by the company.